Featured Journal Articles
Value-Based Pricing of US Prescription Drugs. Estimated Savings Using Reports From the Institute for Clinical and Economic Review
The Inflation Reduction Act allows Medicare to negotiate prices on a limited set of drugs that are not necessarily the highest priced or lowest value. Across payers, interest in lowering drug spending remains high. The National Academy of Medicine recommends basing drug prices on value, tying prices to the magnitude of benefit to preserve incentives […]
12/19/2022The Influence of US Drug Price Dynamics in Cost Effectiveness Analyses of Biologics
Objective: To evaluate the influence of drug price dynamics in cost-effectiveness analyses (CEAs). Methods: We evaluated scenarios involving typical US drug price increases during the exclusivity period and price decreases after the loss of exclusivity (LOE). Worked examples are presented using the Institute for Clinical and Economic Review’s assessments of tezepelumab for the treatment of […]
01/09/2023Patient-centered health technology assessment: a perspective on engagement in health technology assessment by three patient organizations and a health technology assessment body
Patient engagement in health technology assessment (HTA) has become increasingly important over the past 20 years. Academic and practitioner literature has produced numerous case studies and best practice accounts of patient involvement practices around the world. This text analyzes the experience of being involved in an Institute for Clinical and Economic Review (ICER) HTA review […]
11/07/2022